Cargando…
Two Cases of Subsequent Hepatocellular Carcinoma in Immune Checkpoint Inhibitor–Responsive NSCLC: A Case Report
As novel therapeutic regimens continue to lead to increased survival of patients with lung cancer, it is imperative to remain mindful of the accompanying increase in the incidence of new primary malignancies. Although the most common secondary malignancies in patients with lung cancer have historica...
Autores principales: | Cheunkarndee, Tia, Guo, Matthew Z., Birkness-Gartman, Jacqueline E., Oshima, Kiyoko, Lin, Cheng Ting, Marrone, Kristen A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883266/ https://www.ncbi.nlm.nih.gov/pubmed/36718141 http://dx.doi.org/10.1016/j.jtocrr.2022.100448 |
Ejemplares similares
-
Appendiceal adenocarcinoma presenting as a bladder tumor
por: Goddard, Briana, et al.
Publicado: (2022) -
Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020) -
Web-based pathology modules with virtual slides are effective for teaching introductory gastrointestinal pathology concepts
por: Birkness-Gartman, Jacqueline E., et al.
Publicado: (2022) -
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021) -
Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)